The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

• मुख्य लेखकों: Shen Lin (लेखक), Yaping Huang (लेखक), Liangliang Dong (लेखक), Meiyue Li (लेखक), Yahong Wang (लेखक), Dian Gu (लेखक), Wei Wu (लेखक), Dongni Nian (लेखक), Shaohong Luo (लेखक), Xiaoting Huang (लेखक), Xiongwei Xu (लेखक), Xiuhua Weng (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background: Life expectancy for patients with malignant tumors has been significantly improved since the presence of the programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) inhibitors in 2014, but they impose heavy financial burdens for patients, the healthcare system...